Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,001–13,100 of 15,747
Olurotimi, S. A., Zaidat, M. A., Anthonia, I. F., Abdullahi, A., James, A. B., Sabdat, E., Oluwatosin, O., Idigbe, I. E., Olusola, A., Altaf, M., et al. (2024) · medRxiv · doi:10.1101/2024.11.21.24317533 · Cited by 1
COVID-19 vaccine-related pathologies: cardiac and neurological side effects and Long-term COVID-19
Anılanmert, B., Yonar, F. Ç., & Rayimoğlu, G. (2023) · Journal of Research in Pharmacy · doi:10.29228/jrp.544 · Cited by 3
Debbeler, J. P., Streiber, M., Ghazi, S. F.-E., Hiller, H., Press, A. T., Schubert, U. S., Bauer, M. W., Gehring, S., & Traeger, A. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127106 · Cited by 3
Jeong, Y. J., Kim, Y. J., Kim, S., Yoo, J., Lee, J., Lee, S., & Kim, S. I. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.02.005 · Cited by 1
“A comparison of participants aged 16–55 and > 55 years administered the BNT162b2 vaccine found that antibody levels were lower in the older age group [14].”
Zhu, Z., Gao, G., Hu, Y., & Zhao, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328154 · Cited by 1
“Vaccination campaigns have emerged as the cornerstone of efforts aimed at controlling the spread of the virus [5].”
Progress in mRNA delivery systems based on virus-like particles
Wang, X., Wan, Y., Zhang, X., Xu, C., & Li, F. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0632 · Cited by 1
Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
Łukaszuk, K., Podolak, A., Jakiel, G., Kiewisz, J., Wocławek-Potocka, I., Łukaszuk, A., & Rąbalski, Ł. (2021) · Vaccines · doi:10.3390/vaccines9111277 · Cited by 1
“Pfizer/BioNTech, during phase 1 of the vaccine preparation trial, excluded all participants with prior infection, confirmed not only by positive PCR but also serologically [1,3].”
BackgroundMethodResultBogahawaththa, S., Hara, M., Furukawa, T., Iwasaka, C., Sawada, T., Yamada, G., Tokiya, M., Kitagawa, K., Miyake, Y., Kido, M. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12091015 · Cited by 5
Marineci, C. D., Valeanu, A., Negreș, S., & Chiriţă, C. (2021) · Farmacist ro · doi:10.26416/farm.198.1.2021.4353 · Cited by 1
Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boostPreprint
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.03.438330 · Cited by 1
Digregorio, M., Ngoc, P. V., Delogne, S., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100453 · Cited by 1
Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of ConcernsPreprint
Zagorski, K., Pandey, K., Rajaiah, R., Olwenyi, O. A., Bade, A. N., Acharya, A., Johnston, M., Filliaux, S., Lyubchenko, Y. L., & Byrareddy, S. N. (2022) · Research Square · doi:10.21203/rs.3.rs-1206402/v1 · Cited by 1
The development of lipid nanoparticle technology for the management of COVID-19
Yingngam, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00006-3 · Cited by 1
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.1101/2025.08.18.670983 · Cited by 2
Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis
Hakimian, D., Amer, J., Jammal, A., Shafrir, A., Milgrom, Y., Masarowah, M., Hazou, W., Ishay, Y., Imam, A., Francis, A., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100359 · Cited by 1
Bari, R., Bepari, A. K., & Reza, H. M. (2021) · Open Medicine · doi:10.1515/med-2021-0334 · Cited by 1
Katz, A., Aubrey-Bassler, K., Aghajafari, F., Fransoo, G., Ivers, N. M., Kwong, J. C., Moineddin, R., Nguyen, L., Saj, D., Taylor, C. R., et al. (2026) · BMC Public Health · doi:10.1186/s12889-025-24824-4 · Cited by 1
Demirbakan, H., Koçer, İ., Berk, İ., & Bayram, A. (2022) · Klimik Dergisi/Klimik Journal · doi:10.36519/kd.2022.4301 · Cited by 3
Adelglass, J. M., Bradley, P., Cai, M. R., Chau, G., Kalkeri, R., Cloney-Clark, S., Zhu, M., Cai, Z., Eickhoff, M., Plested, J. S., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.03.015 · Cited by 1
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine
Yu, X., Li, N., & Wang, H. (2023) · Biotechnology Law Report · doi:10.1089/blr.2023.29294.hw · Cited by 1
Magen, H., Avigdor, A., Nevo, L., Fried, S., Gibori, A., Levin, E. G., Lustig, Y., Shkury, E., & Rahav, G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284925 · Cited by 1
“Clinical trials with the BNT162b2 mRNA vaccine did not include immunosuppressed subjects [8, 9].”
BackgroundZhu, X., Gao, M., Huang, C., Li, T., Cao, J., Ying, X., Li, T., & Liu, J. (2025) · Chinese Journal of Chemistry · doi:10.1002/cjoc.70302 · Cited by 1
Messenger RNA Lipid-Based Nanoparticles: Optimization of Formulations in the Lab
Delehedde, C., Ciganek, I., Laroui, N., Rameix, N., Perche, F., & Pichon, C. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_12 · Cited by 1
Infectious Complications of HIV Infection
Agwu, A. L., & Dyke, R. B. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00112-9 · Cited by 1
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2021) · bioRxiv · doi:10.1101/2021.12.23.474050 · Cited by 13
“The emergence of the virus variants has contributed to prolonged pandemic even after the brilliant efforts by scientific community in coming up with effective vaccines, therapeutic antibodies and antivirals within a year of the pandemic.(1-10) Emergence of the variants has caused waves of infection throughout the worl…”
BackgroundAzem, A., Ajmal, Z., & Raval, M. (2022) · Cureus · doi:10.7759/cureus.25738 · Cited by 1
“The most common local side effect of Pfizer-BioNTech COVID-19 vaccine was pain at injection site [9].”
BackgroundAge-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
(2022) · doi:10.1101/2022.10.04.22280704 · Cited by 1
“Whereas the Pfizer/BioNTech BNT162b1 vaccine is based on mRNA encoding the complete stabilized S protein encapsulated within lipid nanoparticles (LNP) (10), the ChAdOx1 nCoV- 19 vaccine consists of a replication-deficient chimpanzee adenoviral vector ChAdOx1 encoding the SARS- CoV-2 spike protein (ChAdOx1-S)(11); and…”
BackgroundGeldof, J., Truyens, M., Sabino, J., Ferrante, M., Lambert, J., Lapeere, H., Hillary, T., Laethem, A. V., de Vlam, K., Verschueren, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12101157 · Cited by 1
“Nonetheless, patients receiving these treatments were excluded from the original trials for SARS-CoV-2 vaccine efficacy [31–33].”
BackgroundHow do COVID-19 vaccines affect rheumatic diseases?
Altan, L., Mısırcı, S., Yağcı, İ., et al. (2023) · Archives of Rheumatology · doi:10.46497/archrheumatol.2023.9530 · Cited by 1
Alsalman, B., AlBloushi, A. F., Alzuabi, A., & Tawil, L. (2024) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2024.104265 · Cited by 2
Wanchaijiraboon, P., Sainamthip, P., Teeyapun, N., Luangdilok, S., Poovorawan, Y., Wanlapakorn, N., Pakvisal, P., Susiriwatananont, T., Zungsontiporn, N., Tanasanvimon, S., et al. (2023) · Vaccines · doi:10.3390/vaccines11020356 · Cited by 1
Covid-19 Vaccines: Several technologies at work
Aggarwal, R., & Aggarwal, A. (2021) · The National Medical Journal of India · doi:10.4103/0970-258x.323453 · Cited by 1
Vaccine History: From Smallpox to Covid-19
Puton, C., Saad, F. G. A., Vieira, R. P., Libânio, E. D. S., da Silva, V. B., Cruvinel, W. D. M., Borges, L. L., Taft, C. A., & Gomes, C. M. (2022) · Engineering materials · doi:10.1007/978-3-031-07622-0_21 · Cited by 1
Terada, M., Kondo, N., Wanifuchi‐Endo, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1684671/v1 · Cited by 1
Peptide-encoding gene transfer to modulate intracellular protein-protein interactions
Taya, T., Kami, D., Teruyama, F., Matoba, S., & Gojo, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101226 · Cited by 1
Atual situação da pandemia no Brasil: inovação tecnológica, avanços na ciência e desafios
de Araújo, T. P., Santos, L. C. D., Penido, W. D., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i16.23493 · Cited by 1
Motamed, H., Siami, S., Abdan, Z., Mozafari, F., Khazaei, S., Habibi, R., Rezaeian, S., & Heydarpour, F. (2025) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2025.14.e24 · Cited by 1
“It is suggested that vaccination against COVID-19 implements protection from severe disease [3,16,17], regardless of the viral load [15].”
COVID-19 vaccines and evidence-based medicine
(2021) · doi:10.1101/2021.06.28.21259039 · Cited by 1
Validity and Reliability of the Pfizer Booster Vaccine Effectiveness Questionnaire
Muhammad, R. F., & Ramatillah, D. L. (2023) · Contagion Scientific Periodical Journal of Public Health and Coastal Health · doi:10.30829/contagion.v5i4.15657 · Cited by 2
A Rapid Review of the Effects of the COVID-19 Vaccine Among Individuals Taking Clozapine
Das, A., Sawyer, A. T., & Bagla, P. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001854 · Cited by 1
Lin, Y., Cho, S., Hsieh, Y.-L., Chuang, Y., Hsu, C.-E., Liu, Y.-C., Sung, C.-C., Huang, Y.-H., Ku, W. L., Hsieh, M., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1402194 · Cited by 1
George, T. K., Nair, N. P., Singh, A. K., Kumar, A., Roy, A. D., Mohan, V. N., & Kang, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.062 · Cited by 3
Freire, J., Pang, S., McGee, J. E., Heinrich, M. J., Xie, J., Hammarlund, E., Shaw, D. C., Zhou, Y., Wang, Y., Porter, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.30.685635 · Cited by 1
“For example, a landmark study in 2001 by Kariko et al. reported that injecting mRNA encapsulated in cationic lipofectin into the rat brain leads to immediate protein expression within 1 hour, but the expression becomes largely undetectable after about 24 hours 11 .”
Almadhi, M. A., AlAwadhi, A. I., Stevenson, N. J., Greish, K., Jawad, J. S., Alsayyad, A., Mirza, A., Alsaffar, B., Alalawi, E., Fakhroo, K., et al. (2022) · medRxiv · doi:10.1101/2022.08.24.22279160 · Cited by 2
“This result is comparable to adverse events documented in other reports comparing homologous and heterologous boosting (9, 13, 17-19), and each vaccine independently (20, 21).”
BackgroundResultDeciphering the association between Covid vaccine side effects and menstrual cycle
Priya, S. A., Sinha, N., Mehta, P., & Chandrashekarappa, S. M. (2022) · Biomedicine · doi:10.51248/.v42i3.1290 · Cited by 2
“, (10,11) that younger age group suffer from side effects to the vaccine than the older age group.”
BackgroundKumar, S., Lai, L., Ellis, M., Patel, A. B., Joshi, D., Velden, J. W. V., Faraj, J. A., Wimalasena, S., Pallavi, R. R., Iriss, J., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00749-26 · Cited by 3
Wang, X., Zhou, R., Li, T., et al. (2024) · China CDC Weekly · doi:10.46234/ccdcw2024.196 · Cited by 1
Morabito, K. M., Milutinovic, P. S., Graham, B. S., & Pierson, T. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00065-7 · Cited by 2
Leung, K. S. M., Lee, K., Dabak, S. V., Kong, V., Park, M., Kwok, S. L. L., Silzle, M., Rachatan, C., Cook, A. R., Passanante, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2127117/v1 · Cited by 1
Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?
Bello, A. D., Marion, O., Izopet, J., & Kamar, N. (2022) · Viruses · doi:10.3390/v14091860 · Cited by 1
“The vaccines most frequently deployed were those based on innovative technology using nucleoside-modified mRNA molecules encoding the SARS-CoV-2 spike protein [61].”
BackgroundRivalry between human ideation and virus mutation: two competing means of sustainability
Clermont, P. (2021) · Women Health Care and Issues · doi:10.31579/2642-9756/058 · Cited by 1
Engineered Silyl Lipids to Modulate Liposome and Lipid Nanoparticle Properties for mRNA Delivery
Patterson, L. A., Coppage, D. A., Figueroa, S. M., Cobo, A. A., O’Geen, H., Segal, D. J., & Franz, A. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00932 · Cited by 1
Kayabolen, A., Akcan, U., Ozturan, D., et al. (2021) · bioRxiv · doi:10.1101/2021.01.04.425128 · Cited by 1
Alie, M. S., Tesema, G. A., Abebe, G. F., & Girma, D. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1415427 · Cited by 1
Alshahrani, S. M., Fatease, A. M. A., Orayj, K. M., Alqahtani, A., & Alqahtani, T. (2023) · Vaccines · doi:10.3390/vaccines11030558 · Cited by 1
“The Pfizer and Moderna mRNA vaccines have shown efficacies of 94–95% in preventing symptomatic COVID-19 [30,31].”
BackgroundEnlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination
Valerio, L., Prete, A., Santini, F., Agate, L., Elisei, R., & Latrofa, F. (2023) · Endocrine · doi:10.1007/s12020-023-03367-x · Cited by 1
Кононенко, В. П. (2021) · Ukrainian Journal of International Law · doi:10.36952/uail.2021.4.61-69 · Cited by 1
Orlandi, C., Conti, I., Torre, D., Barocci, S., Magnani, M., Stefanetti, G., & Casabianca, A. (2025) · Vaccines · doi:10.3390/vaccines13101031 · Cited by 2
“Since the SARS-CoV-2 emergency, vaccination strategies—particularly novel mRNA-based vaccines—have drastically reduced COVID-19-associated morbidity and mortality globally [3,21].”
[Prevention by vaccination of adult patients with pulmonary diseases].
Dodt, C., Pletz, M. W., & Kolditz, M. (2021) · PubMed Central · doi:10.1007/s10405-021-00402-4 · Cited by 1
Mai, N. T., Anh, T. T., & Ha, P. T. (2024) · Asian Journal of Ethics in Health and Medicine · doi:10.51847/uikljkzc8a · Cited by 1
Li, Y., Tao, W., Dang, Y., Chen, Y., & Tao, C. (2025) · Research Square · doi:10.21203/rs.3.rs-6096098/v1 · Cited by 1
Mathematical modeling of the effect of multiple vaccines on viral escape
Mohan, T., & Dobrovolny, H. M. (2025) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2025.09.010 · Cited by 2
Webster‐Kerr, K., Grant, A. S., Harris, A., Campbell, E., Henningham, D., Brown, M., Rowe, D., Lord, C., Thorpe, R., Mullings, T., et al. (2025) · Vaccines · doi:10.3390/vaccines13121250 · Cited by 1
“In December 2020, the first vaccines received emergency use authorization for the prevention of COVID-19 based on their efficacy against symptomatic disease [7].”
Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C. ‐., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.24.558921 · Cited by 1
Sahu, T. K., & Rao, A. R. (2024) · Wiley eBooks · doi:10.1002/9781119896869.ch3 · Cited by 1
Birtolo, L. I., Pietro, G. D., Ciuffreda, A., Improta, R., Monosilio, S., Prosperi, S., Cimino, S., Galea, N., Severino, P., Galardo, G., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40409 · Cited by 3
Therapeutic Interventions for COVID-19
Smolić, M., Dawood, R. M., Salum, G. M., El-Meguid, M. A., Omran, M. H., & Smolić, R. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111543 · Cited by 1
Imrie, R. M., Bissett, L. A., Raveendran, S., Manali, M., Amat, J. A. R., Mojsiejczuk, L. N., Logan, N. A., PARK, A. W., Baguelin, M., Viana, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69988-8 · Cited by 2
A Survey of the Side Effects of Pfizer/BioNTech COVID-19 Vaccine among Vaccinated Adults in Iraq
Saleh, A. M., & Shabila, N. P. (2023) · Asia Pacific Journal of Health Management · doi:10.24083/apjhm.v18i3.2145
“In accordance with a report in the New England Journal of Medicine (NEJM), the efficacy of Pfizer and BioNTech vaccines increases significantly from 52% after the first dose to 95% after the second dose; thus, a double dose regimen for COVID-19 is recommended for people aged 16 years and older [8].”
Fryer, H. A., Geers, D., Gommers, L., Zaeck, L. M., Tan, N. H., Jones, B., Goorhuis, A., Postma, D. F., Visser, L. G., Hogarth, P. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.585861 · Cited by 1
Jung, I., Sriramulu, D. K., Lee, S., & Jung, S. T. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00425 · Cited by 1
Bello, U. L., Ja’afar, I. K., Ogbolosingha, A. J., Isa, A., Muhammad, J. H., & Abubakar, A. H. (2024) · Alexandria Journal of Medicine · doi:10.1080/20905068.2024.2317030 · Cited by 2
“The COVID-19 pandemic has led to the accelerated development of a handful of vaccines, which are safe and effective against SARS-CoV-2 [14,15,16].”
Impact of COVID-19 Vaccination on Women During Pregnancy and Breastfeeding
Kumari, U., Sharma, R. K., Sinha, A., et al. (2023) · Cureus · doi:10.7759/cureus.38547 · Cited by 1
“Due to ethical and hypothetical safety issues, pregnant women were previously disallowed from participating in clinical studies for the coronavirus disease 2019 (COVID-19) vaccination [2].”
BackgroundKunyk, D., Vasileva, O., Bespalov, M., Dzharullaeva, A. S., Mazunina, E., Chubarova, A., Seliverstov, M., Smirnykh, D., Shevyrev, D., Shtraus, S., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70335 · Cited by 2
Tan, E. J., Chong, C. Z., Yap, A., Chiew, C. J., Tan, S. H. X., Yang, Y., Tan, K. B., Lye, D. C., Cook, A. R., & Lee, V. (2025) · AJPM Focus · doi:10.1016/j.focus.2025.100419 · Cited by 1
SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort
Simmi, P., Wheeler Sarah, E., Adam, A., Pinto, L., & Shurin Michael, R. (2022) · Insights in Clinical and Cellular Immunology · doi:10.29328/journal.icci.1001020 · Cited by 1
Sun, T., Li, L., Mues, K. E., Georgieva, M. V., Kirk, B., Mansi, J. A., de Velde, N. V., & Beck, E. C. (2024) · medRxiv · doi:10.1101/2024.01.30.24302015 · Cited by 1
Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis
Galleguillos, L., & Alonso, R. N. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103142 · Cited by 2
Parry, R. H., Shang, Y., Sng, J. D. J., McMillan, C. L. D., Modhiran, N., Amarilla, A. A., Isaacs, A., Liang, B., Muller, D. A., Rawle, D. J., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70642 · Cited by 2
Methodical and Immunological Insights of Prime COVID-19 Vaccines
Evangeline, W. P., Divyasri, S., Akshaya, C., Sruthi, S., Barathi, S., Kirubakaran, R., & ArulJothi, K. N. (2023) · Coronaviruses · doi:10.2174/0126667975275824231213112949 · Cited by 1
González-Sánchez, Ó. A., Zaldívar, D., Cuevas, E., & González-Ortiz, L. J. (2024) · Vaccines · doi:10.3390/vaccines12010081 · Cited by 1
Acceptance towards COVID-19 vaccine: A cross-sectional study in the Dominican Republic.
Marte, M. I., Pichardo, E. A., Kandany, V. N., & Castillo, M. M. (2021) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2021.74.7 · Cited by 1
Multilocus adaptation to vaccinationPreprint
McLeod, D. V., & Gandon, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446592 · Cited by 1
Kara, K. T., Bulut, İ., Pirinçci, E., & Ickilli, N. (2023) · Work · doi:10.3233/wor-220111 · Cited by 1
Lokonon, B. E., Alia, M. G., & Kakaï, R. G. (2021) · Preprints.org · doi:10.20944/preprints202103.0509.v1
Ezati, E., Barati, M., Darabı, F., et al. (2024) · Health Science Monitor · doi:10.61186/hsm.3.2.120 · Cited by 1
Deng, L., Xiong, Y., Chen, T., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-176224/v1 · Cited by 1
Kanemaru, N., Yoshikawa, T., Miki, S., Nakao, T., Nakamura, Y., Fujimoto, K., & Abe, O. (2024) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.mp.2023-0147 · Cited by 1
“19,20 Considering the general process of vaccination-related immune reaction, the increase in signal intensity on T2-weighted images of the enlarged lymph nodes is thought to decrease over time and return to a normal range.”
Hvor effektive er covid-19-vaksinene hos eldre?
Vaksdal, H. H., & Grødeland, G. (2021) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0748 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.